Home Medicine A case of primary central nervous system lymphoma mimic neuromyelitis optica
Article Open Access

A case of primary central nervous system lymphoma mimic neuromyelitis optica

  • Xixi Sheng , Mingwei Xu and Xia Li EMAIL logo
Published/Copyright: February 18, 2020

Abstract

Primary central nervous system lymphoma (PCNSL) is rare. And the symptoms of PCNSL are atypical, it is extremely easy to be misdiagnosed as other diseases. However, early treatment is crucial which is requesting early diagnosis. We report a case of a 47-year-old man who was initially diagnosed as neuromyelitis optica (NMO) on the basis of clinical findings, slightly high Aquaporin4 (AQP4) (1:10) and high signals of magnetic resonance imaging. Though his symptoms progressively improved after steroid pulse treatment, but worse when steroid was decreased to 40 mg per day. We considered the patient should be diagnosed as PCNSL. After the examination of magnetic resonance spectroscopy (MRS) and positron emission tomography (PET), the results indicated PCNSL was most possible. Therefore we gave him stereotactic biopsy of deep of supratentorial, which showed non-Hodgkin malignant B-cell lymphoma.

1 Introduction

Primary central nervous system lymphoma (PCNSL) is rare [1]. The symptoms of PCNSL are atypical as was easy to be misdiagnosed as other diseases [2]. There are some cases of PCNSL that are misdiagnosed as other diseases, such as Parkinson’s disease, myasthenia and multiple sclerosis [3]. There are some reasons. First, PCNSL represents less than 2% of all brain neoplasms and 1%–2% of malignant lymphomas. Most are B cell non-Hodgkin lymphoma (NHL), which may present as single or multiple lesions involving the eye, leptomeninges, or brain parenchyma. Localization primarily in the brain stem occurs in 3% of PCNSL, and most are T cell in origin [4]. In the present work, we present a rare case of primary central nervous system lymphoma which mimic neuromyelitis optica.

2 Case Report

A 47-year-old man presented with a 1-week history of neck pain and 2-day history of shoulders pain. He showed upper limb weakness and under the right chest numbness. However, He had no history of smoking and drinking, as well as persistent weight loss. He also denied the history of hypertension and diabetes.

On neurological examination, the patient was found to have a shallow of the left frontal line and nasolabial groove and hypaesthesia under T4 the right chest. Muscular tension was normal, but upper limbs muscle strength was 4-/5 and lower limbs muscle strength was 5-/5. Tendon reflexes were normal and both Kernig’s and Brudzinski’s signs were negative, but bilateral Babinski signs and left Hoffmann sign were positive. Analyses of viral antibodies, syphilis serology, and human immunodeficiency virus antibodies were negative. Lumbar puncture showed normal intracranial pressure. In the CSF findings (Table 1), tumor cells were not observed. Red cells were 10/ul and nuclear cells were 220/ul, however, the classification flow cytometry of cerebrospinal fluid leukemia had not found abnormal differentiation of cells. The protein level was slightly elevated (91 mg/ dL), however, chloride (127 mmol/L) and glucose (3.32 mmol/L) were normal. Oligo-clonal bands were not present. Other markers of autoimmune diseases, such as antinuclear antibodies, extractable nuclear antigen, and antineutrophil cytoplasmic antibodies, were all negative. However, some cytokines were slightly high (IL-2(0.1pg/ ml), IL-6 (67.75 pg/ml), TNF-α (50.66pg/ml), others (IL-2, IL-10, IL-17 and IFN-γ) were normal. Serum anti-AQP4 antibodies were slightly positive (1:10) on April 6th 2016,

Table 1

The results of the CSF findings

Examination CSF/serum Results
Tumor cells CSF Negative
Red cells CSF 10/ul
Nuclear cells CSF 220/ul
Protein CSF 91mg/dL
Chloride CSF 127mmol/L
Glucose CSF 3.32mmol/L
Oligo-clonal bands CSF Negative
Antinuclear antibodies serum Negative
Extractable nuclear antigen serum Negative
Antineutrophil cytoplasmic antibodies serum Negative
Il-2 serum 0.1pg/ml
Il-6 serum 67.75pg/ml
TNF-α serum 50.66pg/ml
Anti-aqp4 antibodies serum Positive
  1. CSF: cerebrospinal fluid

which was consistent with the diagnosis of NMO. Magnetic resonance imaging of the cervical spinal cord revealed multiple lesions occupied in C2-T1 spinal and brain stem, high in T2 weighed, enlargement of the cervical spinal and evident enhancement in the enhanced imaging (Figure1). Magnetic resonance scans showed bilateral thalamus, periventricular, basal ganglia, pedunculus cerebri with hypersignals using fluid-attenuated inversion recovery (Figure 2 A and B). Combination of the clinical symptoms, neurological examination, laboratory examination and magnetic resonance imaging, the initial diagnosis was considered as neuromyelitis optica with steroid pulse treatment (methylprednisolone 1g intravenous injection per day) and immunoglobulin. After steroid treatment, his symptoms progressively improved and he returned home.

Figure 1 
          MRI of cervical spinal cord demonstrated multiple lesions with occupied in C2-T1 spinal and brain stem. (March 26th) A: Sagittal T2 weighed showed enlargement of the cervical spinal. (April 1st) B and C: Sagittal T1 enhanced imaging showed the enhanced lesion in C2-T1 level and brain stem and slightly enlargement of the cervical spinal. (April 29th) D: Sagittal T1 enhanced imaging showed multiple abnormal enhanced lesion in C2 below and in the intrathoracic spinal and brain stem, compared with 2016-04-01 images, lesions increased. (May 19th) E: Positron emission tomography (PET) showed obvious increased 18-Fludeoxyglucose (18F-FDG) uptake in the C1-C7, T2-T3, T7 spinal cord. (July 20th) F: Sagittal T2 showed multiple abnormal enhanced lesion in C2 below and in the intrathoracic spinal and brain stem, compared with 2016-04-29 images, lesions decreased.
Figure 1

MRI of cervical spinal cord demonstrated multiple lesions with occupied in C2-T1 spinal and brain stem. (March 26th) A: Sagittal T2 weighed showed enlargement of the cervical spinal. (April 1st) B and C: Sagittal T1 enhanced imaging showed the enhanced lesion in C2-T1 level and brain stem and slightly enlargement of the cervical spinal. (April 29th) D: Sagittal T1 enhanced imaging showed multiple abnormal enhanced lesion in C2 below and in the intrathoracic spinal and brain stem, compared with 2016-04-01 images, lesions increased. (May 19th) E: Positron emission tomography (PET) showed obvious increased 18-Fludeoxyglucose (18F-FDG) uptake in the C1-C7, T2-T3, T7 spinal cord. (July 20th) F: Sagittal T2 showed multiple abnormal enhanced lesion in C2 below and in the intrathoracic spinal and brain stem, compared with 2016-04-29 images, lesions decreased.

Figure 2 
          Magnetic resonance imaging revealed that right basal ganglia, pons, cerebellar peduncles with abnormal signals.(April 5th) A and B: Magnetic resonance scans showed bilateral thalamus, periventricular, basal ganglia, pedunculus cerebri with hypersignals using fluid attenuated inversion recovery.(May 19th)C: Positron emission tomography (PET) showed a slightly high enhancement in the right basal ganglia and right pons, about the size of which is 2.1*2.0*2cm and the maximum SUV value is 23.6. (May 23th) D, E, F and G: A month and a half later, axial T1 and T2 magnetic resonance imaging revealed that right basal ganglia, pons, cerebellar peduncles with hypersignals, and lesions were larger than the former, even involved in bilateral thalamus. This enlargement would be suggestive of a neoplastic process. (July 20th) H: Axial T2 magnetic resonance imaging revealed that right basal ganglia, pons, cerebellar peduncles with abnormal signal, compared with 2016-05-23, lesions decreased.
Figure 2

Magnetic resonance imaging revealed that right basal ganglia, pons, cerebellar peduncles with abnormal signals.(April 5th) A and B: Magnetic resonance scans showed bilateral thalamus, periventricular, basal ganglia, pedunculus cerebri with hypersignals using fluid attenuated inversion recovery.(May 19th)C: Positron emission tomography (PET) showed a slightly high enhancement in the right basal ganglia and right pons, about the size of which is 2.1*2.0*2cm and the maximum SUV value is 23.6. (May 23th) D, E, F and G: A month and a half later, axial T1 and T2 magnetic resonance imaging revealed that right basal ganglia, pons, cerebellar peduncles with hypersignals, and lesions were larger than the former, even involved in bilateral thalamus. This enlargement would be suggestive of a neoplastic process. (July 20th) H: Axial T2 magnetic resonance imaging revealed that right basal ganglia, pons, cerebellar peduncles with abnormal signal, compared with 2016-05-23, lesions decreased.

However, when steroid was decreased to 40 mg per day, his symptoms worsened and he was admitted to our hospital again. He presented with limbs weakness, spirit weakness and vision loss in the left eye in 2 months. His limb muscle strength gradually declined to grade 0 2 months later. Review serum anti-AQP4 antibodies were negative on May 20th 2016. Magnetic resonance imaging revealed that right basal ganglia, pons, cerebellar peduncles with hypersignals, and lesions were larger than 2 months ago (Figure 2 C, D, E and F). The MRS showed a high resonance of free lipids and Cho/NAA ratio (4.8-5.1), lactates were also visible, which was in favor of a tumoral process (Fig4). Positron emission tomography (PET) showed a slightly increased 18-Fludeoxyglucose (18F-FDG) uptake in the right basal ganglia and right pons and obviously increased uptake of 18F-FDG in the affected brain, the maximum SUV (Standardized Uptake Value) value is 23.6, indicating PCNSL possible (Figure1E and Figure 2C). (May 27th) Stereotactic biopsy of deep of supratentorial was performed and immunohistochemical analysis showed that the brain tissue was infiltrated with multiple foci of heterotypic cells with CD20 (+), 6-1 CD79a (+), Ki-67 (90%+++), BcL-2 (80%+) (Figure 5), suggestive of non-Hodgkin malignant B-cell lymphoma. (May 29th) After a stereotactic biopsy, the patient appeared unconscious. Arterial blood gas showed partial pressure of carbin dioxide (pCO2) elevated. After endotracheal intubation and mechanical ventilation, the patient’s pCO2 gradually decreased and the patient turned to awake. Neurosurgical consultation considered: combination of symptoms and CT scan which showed the right basal ganglia and right temporal lobe hemorrhage with edema to consider (Figure 3A), first consider as piercing bleeding. According to these results, the patient was given chemotherapy. The patient was not given radiotherapy, because he had a severe lung infection. Methotrexate was used at a high dose (5 g/m2) and the hypaesthesia plane was down to T2 the right chest. Then he has given rituximab 600 mg and the second course of Methotrexate at a high dose (5 g/m2). After the third course of methotrexate cycle, his symptoms were not improved further. He was given intrathecal injection of MTX 15mg + Ara-e 50mg + DXM10 mg. Later, CT scan image, compared to 2016-05-29 CT image, bleeding fade, edema reduced, which also supported the previous diagnosis of piercing bleeding (Figure 3B and C). However, Magnetic resonance imaging of the brain and spinal cord showed that the lesions of the right thalamus and midbrain were decreased (Figure1F and Figure2H) and oblongata and the cervical cord had no change, his symptoms still were not improved. Unfortunately, 9 months after the first admission, he died of the disease.

Figure 3 
          CT scan showed the right basal ganglia and right temporal lobe hemorrhage with edema (May 29th) A:Brain CT scan showed the right basal ganglia flake slightly higher density, CT value of about 32U, surrounding low-density, right temporal lobe low-density, the intracranial brain parenchyma density was not significantly abnormal changes. Midline slightly shifted to the left. (June 14th) B and (June 27th) C: Brain CT scan image is about similar to the image in 5.29, bleeding fade, edema reduced.
Figure 3

CT scan showed the right basal ganglia and right temporal lobe hemorrhage with edema (May 29th) A:Brain CT scan showed the right basal ganglia flake slightly higher density, CT value of about 32U, surrounding low-density, right temporal lobe low-density, the intracranial brain parenchyma density was not significantly abnormal changes. Midline slightly shifted to the left. (June 14th) B and (June 27th) C: Brain CT scan image is about similar to the image in 5.29, bleeding fade, edema reduced.

Figure 4 
          The MRS showed a high resonance of free lipids and Cho, a low resonance of NAA, and a high Cho/NAA ratio (4.8-5.1) .
Figure 4

The MRS showed a high resonance of free lipids and Cho, a low resonance of NAA, and a high Cho/NAA ratio (4.8-5.1) .

Figure 5 
          Pathology of the brain showing:(Right basal brain tissue): Non-Hodgkin's lymphoma, Diffuse large B cell type. CD3 (-), CD20 (+), 6-1 CD79a(+), CD30(Ki-1)( -), CD5(-), CD10(-), BcL-2 (80%+), Bcl-6 (-), ALK(-), MUM1 (+), Ki-67 (90%+++), PAX-5 (+), Myc (40%+), CyclinD1 (-).
Figure 5

Pathology of the brain showing:(Right basal brain tissue): Non-Hodgkin's lymphoma, Diffuse large B cell type. CD3 (-), CD20 (+), 6-1 CD79a(+), CD30(Ki-1)( -), CD5(-), CD10(-), BcL-2 (80%+), Bcl-6 (-), ALK(-), MUM1 (+), Ki-67 (90%+++), PAX-5 (+), Myc (40%+), CyclinD1 (-).

Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.

Informed consent: Informed consent has been obtained from the family members of the patient included in this study

3 Discussion

Primary central nervous system lymphoma (PCNSL) is rare clinically without the exact incidence rate [1]. PCNSL is not firstly considered in most of the clinical cases because we often diagnose diseases as single and common diseases. In the usual case of neurologists, PCNSL are usually the last to consider. Second, PCNSL may present with all symptoms, such as limb weakness, hemianopsia, hypersomnia, and binocular vertical diplopia. Though typical optic neuromyelitis showing acute severe long myelitis and bilateral or simultaneous symptoms, some patient’s symptoms may slowly progress from one side to the other. Symptoms can prompt us for some disease, but not the only criteria for diagnosing the disease. So we diagnose diseases with a combination of symptoms, laboratory tests and radiographic. Third, some laboratory tests may be also prone to other diseases. Although the NMO is also not frequently diagnosed clinically with the incidence of 2.56 out of 100,000 persons [5]. NMO-IgG has been reported to be a novel serological marker for NMO [6]. But there have been several case reports of NMO-IgG coincident with cancer, suggesting NMO-IgG possibly being a paraneoplastic marker [7, 8, 9]. Neoplastic cells may provide the antigen initiating an aquaporin-4 immune response. Tumor cells express, as onconeural antigens, proteins that are normally expressed by mature neurons, glia, or muscle. Cancer-directed immune responses initiated by those antigens have the potential to target autoantigens in the nervous system [10]. In this case, AQP4 serum-positive(1:10) may be caused by PCNSL rather than NMO. But it is not denied that AQP4 serum-positive can help diagnose NMO. Finally, the radiographic examination maybe not typical in some cases. The radiographic of the patient was over three vertebral segments, slightly high in T2 weighted and enlargement of the cervical spinal, which is not typical. The radiological spectrum of the CNS lesion in NMO is very wide. Longitudinally extensive transverse myelitis, over 3 vertebral segments, and optic neuritis, extensive and involving posterior segment, are essential findings for the diagnosis [11]. So the current case is an unusual presentation of primary brain stem B cell non-Hodgkin’s lymphoma, which was initially misdiagnosed as NMO on the basis of clinical findings, slightly high AQP4 and magnetic resonance imaging that accorded with the characteristic imaging of NMO. This case needs to attach clinical neurologists great attention to some points: when we diagnose a patient as NMO, we also should differentiate from PCNSL. We need other more effective methods to help differentiate NMO and PCNSL. By assessing some metabolic changes for many pathological processes, localized Proton Magnetic Spectroscopy (MRS) has been successfully used as a more sensitive and non-invasive tool for differential diagnosis [12]. In some cases, after the steroid pulse treatment, the symptoms are still progressive, we could suggest patient to have a test of MRS. If the MRS of the patient shows a high resonance of free lipids and visible lactate, especially a high Cho/NAA ratio, PCNSL should be considered [12]. Except for MRS, it showed that the CSF sIL-2R level is a biomarker that can differentiate CNS IDDs (inflammatory demyelinating diseases) from CNS lymphoma. CSF sIL-2R is founded higher than in the patient of PCNSL than of CNS IDDs [13]. NMO is one of CNS IDDs, so CSF sIL-2R maybe also can help differentiate PCNSL from NMO. However, the final diagnose is needed a stereotactic biopsy. Immunohistochemical analysis not only can help diagnose the patient as PCNSL, but also can certain the pathological type. All these tests can help differentiate CNS lymphoma from NMO, but most important thing is that we have a concept that we should differentiate a common diagnose from PCNSL and we know the best time when we should give the patient the examination of MRS, CSF sIL-2R and stereotactic biopsy.

There are several possible causes of this patient’s intracranial hemorrhage. First, the most likely cause of intracranial hemorrhage in this patient is puncture bleeding according to the history of stereotactic biopsy and the CT image after two weeks. And it is also based on the site of intracranial hemorrhage in the puncture site. Second, the patient’s intracranial hemorrhage cannot rule out the possibility of tumor necrosis bleeding because of the PCNSL invasion of the basal ganglion. Intratumoral hemorrhage may be seen, which is rare in the immunocompetent patient [14]. This patient’s analyses of viral antibodies, syphilis serology, and human immunodeficiency virus antibodies were negative. The possibility of intratumoral hemorrhage is small. Third, it may also be due to thrombocytopenia caused by chemotherapy drugs, such as Methotrexate, which induce intracranial hemorrhage. However, this patient tested blood routinely, so this possibility is also small.

  1. Conflict of interest: Authors state no conflict of interest

References

[1] Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1-v100.10.1093/neuonc/noz150Search in Google Scholar PubMed PubMed Central

[2] Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol 2019;184:348-363.10.1111/bjh.15661Search in Google Scholar PubMed

[3] Citterio G, Calimeri T, Ferreri A. Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. Expert Rev Neurother 2018:1-15.10.1080/14737175.2018.1462700Search in Google Scholar PubMed

[4] Shams PN, Waldman A, Plant GT. B Cell lymphoma of the brain stem masquerading as myasthenia. J Neurol Neurosurg Psychiatry 2002;72:271-3.10.1136/jnnp.72.2.271Search in Google Scholar PubMed PubMed Central

[5] Kim JE, Park SH, Han K, Kim HJ, Shin DW, Kim SM. Prevalence and incidence of neuromyelitis optica spectrum disorder and multiple sclerosis in Korea. Mult Scler 2019:1352458519888609.10.1177/1352458519888609Search in Google Scholar PubMed

[6] Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.10.1016/S0140-6736(04)17551-XSearch in Google Scholar PubMed

[7] De Santis G, Caniatti L, De Vito A, De Gennaro R, Granieri E, Tola MR. A possible paraneoplastic neuromyelitis optica associated with lung cancer. Neurol Sci 2009;30:397-400.10.1007/s10072-009-0112-0Search in Google Scholar PubMed

[8] Mueller S, Dubal DB, Josephson SA. A case of paraneoplastic myelopathy associated with the neuromyelitis optica antibody. Nat Clin Pract Neurol 2008;4:284-8.10.1038/ncpneuro0765Search in Google Scholar PubMed

[9] Antoine JC, Camdessanché JP, Absi L, Lassablière F, Féasson L. Devic disease and thymoma with anti-central nervous system and antithymus antibodies. Neurology 2004;62:978-80.10.1212/01.WNL.0000115168.73299.88Search in Google Scholar

[10] Pittock SJ, Lennon VA. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008;65:629-32.10.1001/archneur.65.5.629Search in Google Scholar PubMed

[11] Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.10.1212/WNL.0000000000001729Search in Google Scholar PubMed PubMed Central

[12] Taillibert S, Guillevin R, Menuel C, Sanson M, Hoang-Xuan K, Chiras J, et al. Brain lymphoma: usefulness of the magnetic resonance spectroscopy. J Neurooncol 2008;86:225-9.10.1007/s11060-007-9468-2Search in Google Scholar PubMed

[13] Ikeguchi R, Shimizu Y, Shimizu S, Kitagawa K. CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma. Mult Scler 2018;24:1212-1223.10.1177/1352458517717804Search in Google Scholar PubMed

[14] Tang YZ, Booth TC, Bhogal P, Malhotra A, Wilhelm T. Imaging of primary central nervous system lymphoma. Clin Radiol 2011;66:768-77.10.1016/j.crad.2011.03.006Search in Google Scholar PubMed

Received: 2019-08-12
Accepted: 2020-01-27
Published Online: 2020-02-18

© 2020 Xixi Sheng, et al. published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Research Articles
  2. Changing the tone of clinical study design in the cannabis industry
  3. Integrated Chinese and western medicine for acute guillain-barré syndrome treatment
  4. Hydrochloride fasudil attenuates brain injury in ICH rats
  5. Protective role of maize purple plant pigment against oxidativestress in fluorosis rat brain
  6. A novel low-cost electrode for recording the local field potential of freely moving rat’s brain
  7. Neuroprotective mechanisms of erythropoietin in a rat stroke model
  8. Plasma cholesterol in Alzheimer’s disease and frontotemporal dementia
  9. Dysbiosis characteristics of gut microbiota in cerebral infarction patients
  10. miR-142-3p suppresses apoptosis in spinal cord-injured rats
  11. Decreased MiR-30a promotes TGF-β1-mediated arachnoid fibrosis in post-hemorrhagic hydrocephalus
  12. Effect of C-phycocyanin on HDAC3 and miRNA-335 in Alzheimer’s disease
  13. EGCG modulates PKD1 and ferroptosis to promote recovery in ST rats
  14. Efficacy of Novavit in ameliorating the neurotoxicity of propionic acid
  15. High-fat diet-induced obesity and impairment of brain neurotransmitter pool
  16. Erratum to “Changing the tone of clinical study design in the cannabis industry”
  17. Development of a trunk motor paradigm for use in neuroimaging
  18. Notoginsenoside R1 attenuates sevoflurane-induced neurotoxicity
  19. Saikosaponin A attenuates neural injury caused by ischemia/reperfusion
  20. Safety profile of the transcription factor EB (TFEB)-based gene therapy through intracranial injection in mice
  21. Partial enzyme digestion facilitates regeneration of crushed nerve in rat
  22. Correlation between calcium, water contents and ultrasonographic appearance of atherosclerotic lesions of carotid artery lesions
  23. Diabetes does not affect motor recovery after intracerebral hemorrhage
  24. IRF8 is crucial for the nicotine withdrawal-induced hyperalgesia in mice
  25. Prediction of muscle loss after stroke by analysis of corticospinal tract
  26. Interleukin-27 levels in patients with myasthenia gravis
  27. Artesunate attenuates traumatic brain injury-induced impairments in rats
  28. BDMC protects AD in vitro via AMPK and SIRT1
  29. Injury of the optic radiation in patients with mild TBI: A DTT study
  30. Time-restricted feeding alters isoflurane-induced memory deficits
  31. Video-based education improves the image quality of diagnostic percutaneous cerebral angiography among elderly patients
  32. The effect of rTMS in the management of pain associated with CRPS
  33. EGCG treats ICH via up-regulating miR-137-3p and inhibiting Parthanatos
  34. Modified hemispherectomy for infantile hemiparesis and epilepsy
  35. Isovitexin modulates autophagy in Alzheimer’s disease via miR-107 signalling
  36. Epitranscriptome of the ventral tegmental area in a deep brain-stimulated chronic unpredictable mild stress mouse model
  37. Role of prefrontal cortex during Sudoku task: fNIRS study
  38. Tongxinluo promotes axonal plasticity and functional recovery after stroke
  39. Eriodictyol corrects functional recovery and myelin loss in SCI rats
  40. Letter to the Editor
  41. Ataxic hemiparesis after corona radiata infarct: Diffusion tensor imaging correlation of corticoponto-cerebellar tract injury
  42. Compression of the lateral antebrachial cutaneous nerve by a traumatic arteriovenous fistula
  43. Rapid Communication
  44. Anticholinergic drugs and oral health-related quality of life in patients with schizophrenia: a pilot study
  45. Deviant cortical sulcation related to schizophrenia and cognitive deficits in the second trimester
  46. Case Report
  47. A case of primary central nervous system lymphoma mimic neuromyelitis optica
  48. A Moving Residual Limb: Botulinum Toxin to the Rescue
  49. Clinical and imaging features of reversible splenial lesion syndrome with language disorder
  50. Impaired consciousness due to injury of the ascending reticular activating system in a patient with bilateral pontine infarction: A case report
  51. Commentary
  52. A comment on Morey et al. (2020)
  53. Review Articles
  54. Advances in transcription factors related to neuroglial cell reprogramming
  55. The “authentic subjective experience” of memory in Alzheimer’s disease
  56. Chronic neurological diseases and COVID-19: Associations and considerations
  57. Special Issue "Neuroinflammation: from basic to clinical perspectives"
  58. Ormosanine improves neuronal functions in spinal cord-injured rats by blocking peroxynitrite/calpain activity
  59. Retraction
  60. Retraction of: Identification of biological markers for better characterization of older subjects with physical frailty and sarcopenia
Downloaded on 16.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/tnsci-2020-0005/html
Scroll to top button